


64 year old female, history given: Study Candidate

William Millard 7/29/2016





Digging Deeper


 Operative Report February 2016 described a subchondroplasty procedure utilizing Accufill calcium phosphate substrate.

 Procedure performed on the medial femoral condyle and medial tibial plateau.

Subchondroplasty Accufill Calcium Phosphate







Use

Indications


- Chondral defects
- Osteochondral defects
- Osteochondritis dissecans
- Osteoarthritis
- Insufficiency fractures
- Stress fractures
- Subchondral defects
- Avascular necrosis
- Spontaneous osteonecrosis of the knee

Contraindications

- Acute tibial plateau fractures
- Acute distal femur fractures
- Undiagnosed bone lesions
- Infection
- Malignancy

Manufacturers Description

"During The SCP® Procedure, AccuFill® BSM, an injectable, flowable, engineered calcium phosphate bone substitute is used to fill a subchondral bone defect. AccuFill® BSM crystallizes and hardens in an endothermic reaction at 37° C to form a nanocrystalline, macroporous scaffold in the bone. Over time, through cell-mediated remodeling, AccuFill® BSM is resorbed and replaced with new bone."



Procedure



Contents lists available at ScienceDirect

Clinical Imaging

journal homepage: http://www.clinicalimaging.org



Case Report

MRI findings of subchondroplasty of the knee: a two-case report




Mika T. Nevalainen ^{a,*}, Peter F. Sharkey ^b, Steven B. Cohen ^b, Johannes B. Roedl ^a, Adam C. Zoga ^a, William B. Morrison ^a

"To our knowledge, the MRI findings of knee subchondroplasty have never been described in the radiological literature. The purpose of this study is to describe the characteristic findings of knee subchondroplasty seen on MRI."

a Division of Musculoskeletal Imaging and Intervention, Department of Radiology, Thomas Jefferson University Hospital, Sidney Kimmel Medical College at Thomas Jefferson University, 132 South 10th Street, Philadelphia, PA 19107, USA


b Rothman Institute, Department of Orthopedic Surgery, Thomas Jefferson University Hospital, Sidney Kimmel Medical College at Thomas Jefferson University, 925 Chestnut Street, Philadelphia, PA 19107, USA

42-year-old man



4 months postprocedure


42-year-old man



6 months after

Nevalainen, Mika T., Peter F. Sharkey, et al. "MRI Findings of Subchondroplasty of the Knee: A Two-case Report." Clinical Imaging 40.2 (2016)

58-year-old man




preprocedure 9 months 14 months


Returning to Our Case


Right Knee MRI January 2016











References

- Nevalainen, Mika T., Peter F. Sharkey, Steven B. Cohen, Johannes B. Roedl, Adam C. Zoga, and William B. Morrison. "MRI Findings of Subchondroplasty of the Knee: A Two-case Report." *Clinical Imaging* 40.2 (2016): 241-43. Web.
- 2. Zimmer Biomet http://subchondroplasty.com
- 3. Cole BJ, Harris JD, eds. Biologic Knee Reconstruction: A Surgeon's Guide (pp 83-89). "Subchondral Bone Treatment"

AccuFill® BSM Performance

Criteria	Feature	Benefit
Formulation	Proprietary next generation apatite. Mimics chemical structure of human bone.	Facilitates cell-mediated remodeling.
Handling	Truly injectable. Remains cohesive. Flowable inside cancellous bone. 15 minutes of working time.	No need to remove subchondral bone. No phase separation from injection pressure. Interdigitates easily for complete defect fill. Long window for implantation; intraoperative flexibility.
Setting	Endothermically sets in 10 minutes at 37°C.	Sets hard after closure, no thermal necrosis.
Structure	Osteoconductive. Nanocrystalline structure. 65% total porosity; 1-300 µm pore size. 10 MPa compressive strength.	Nanocrystalline structure and high surface area facilitate remodeling and bony ingrowth. Physical properties comparable to cancellous bone.
Remodeling	Cell-mediated remodeling. Remodeled vs. dissolved.	Remodels with new bone growth.

AccuFill® BSM = $Ca_{10-x}(M)_x(PO_4)_{6-x}(HPO_4,CO_3)_x(OH)_{2-x} = Bone^{*1}$

AccuFill® BSM is manufactured by Etex, a subsidiary of Zimmer Biomet and leader in bioresorbable bone substitute materials. The company is headquartered in MIT´s University Park in Cambridge, Massachusetts, a world renowned center for biotech research and innovation.